These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8800191)

  • 1. Genotoxicology and risk assessment in the era of the human genome project.
    Vorce RL; Stemmer PM
    J Toxicol Clin Toxicol; 1996; 34(5):521-3. PubMed ID: 8800191
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of the highly polymorphic S-mephenytoin hydroxylase in humans.
    Soucek P; Guo Z; Sandhu P; Martin MV; Cosme J; Beaune PH; Guengerich FP
    Arch Toxicol Suppl; 1996; 18():437. PubMed ID: 8678819
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.
    Goldstein JA; Blaisdell J
    Methods Enzymol; 1996; 272():210-8. PubMed ID: 8791779
    [No Abstract]   [Full Text] [Related]  

  • 4. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics of cytochromes P450.
    Hasler JA
    Mol Aspects Med; 1999; 20(1-2):12-24, 25-137. PubMed ID: 10575648
    [No Abstract]   [Full Text] [Related]  

  • 6. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.
    Ford GA; Wood SM; Daly AK
    Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
    Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro measurement of CYP2C19 activity.
    Wedlund PJ; Wilkinson GR
    Methods Enzymol; 1996; 272():105-14. PubMed ID: 8791767
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between CYP2C19 genotype and proguanil oxidative polymorphism.
    Coller JK; Somogyi AA; Bochner F
    Br J Clin Pharmacol; 1997 Jun; 43(6):659-60. PubMed ID: 9205829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients.
    Mamiya K; Ieiri I; Miyahara S; Imai J; Furuumi H; Fukumaki Y; Ninomiya H; Tashiro N; Yamada H; Higuchi S
    Pharmacogenetics; 1998 Feb; 8(1):87-90. PubMed ID: 9511186
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual and ethnic differences in CYP2C19 activity in Chinese populations.
    Shu Y; Zhou HH
    Acta Pharmacol Sin; 2000 Mar; 21(3):193-9. PubMed ID: 11324414
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 15. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity.
    Bathum L; Andersen-Ranberg K; Boldsen J; Brøsen K; Jeune B
    Eur J Clin Pharmacol; 1998 Jul; 54(5):427-30. PubMed ID: 9754988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human liver mephenytoin 4'-hydroxylase cytochrome P-450 proteins and genes.
    Brian WR; Ged C; Bellew TM; Srivastava PK; Bork RW; Umbenhauer DR; Lloyd RS; Guengerich FP
    Drug Metab Rev; 1989; 20(2-4):449-65. PubMed ID: 2680390
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
    Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
    Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods.
    Marzo A; Balant LP
    J Chromatogr B Biomed Appl; 1996 Mar; 678(1):73-92. PubMed ID: 8861658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.